scispace - formally typeset
A

Aryeh Fischer

Researcher at University of Colorado Denver

Publications -  132
Citations -  8479

Aryeh Fischer is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Interstitial lung disease & Connective tissue disease. The author has an hindex of 39, co-authored 128 publications receiving 6546 citations. Previous affiliations of Aryeh Fischer include University of Colorado Boulder & Paris Diderot University.

Papers
More filters
Journal ArticleDOI

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

TL;DR: In this article, the authors used a modified intention-to-treat analysis using an inferential joint model combining a mixed-effects model for longitudinal outcomes and a survival model to handle non-ignorable missing data.
Journal ArticleDOI

Toll-like receptor 7 (TLR7)–driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity

TL;DR: It is demonstrated that aged female mice acquire a previously uncharacterized population of B cells that are called age-associated B cells (ABCs) and that these cells express integrin α(X) chain (CD11c) chain, and this unexpected population also appears in young lupus-prone mice.
Journal ArticleDOI

Rheumatoid arthritis-interstitial lung disease-associated mortality.

TL;DR: Clinically significant RA-ILD occurs in nearly 10% of the RA population, and is associated with shortened survival and more severe underlying disease, whereas overall mortality rates for RA have fallen, those associated withRA-ILD have increased significantly in older age groups.
Journal ArticleDOI

Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease

TL;DR: Small series suggest mycophenolate mofetil (MMF) is well tolerated and may be an effective therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD) and is associated with either stable or improved pulmonary physiology over a median 2.5 years of followup.